Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 4/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CDC25A | P30304 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | CDC25C | P30307 | 1/20 | 0.37 |
| ▸ | TK1 | P04183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62475 | 1.00 | MGLL (0.43) | MGLLFAAHTRPV1EPHX2CDC25A | |
| SCHEMBL9215043 | 0.90 | MGLL (0.45) | MGLLFAAHTRPV1EPHX2CDC25A | |
| SCHEMBL9215037 | 0.90 | MGLL (0.45) | MGLLFAAHTRPV1EPHX2CDC25A | |
| SCHEMBL9202828 | 0.90 | ALDH1A1 (0.39) | MGLLFAAH | |
| SCHEMBL9205022 | 0.90 | ALDH1A1 (0.39) | MGLLFAAH | |
| SCHEMBL9202960 | 0.90 | ALDH1A1 (0.39) | MGLLFAAH | |
| SCHEMBL1525180 | 0.88 | ALDH1A1 (0.40) | MGLLFAAH | |
| SCHEMBL60992 | 0.83 | ALDH1A1 (0.41) | — | |
| SCHEMBL9213345 | 0.79 | ACHE (0.40) | MGLLFAAH | |
| SCHEMBL9211600 | 0.79 | ACHE (0.40) | MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS, LLC | 2023-07-13 | — | — | US | disclosed |
| US-11612608-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2023-03-28 | — | — | US | disclosed |
| US-20200215077-A1 | METHODS OF TREATING ORAL MUCOSITIS | BIOSSIL INC. (CA) | 2020-07-09 | — | — | US | disclosed |
| US-10610533-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3527079-A1 | METHODS OF TREATING ORAL MUCOSITIS | Galera Labs, LLC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-2056675-B1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180333421-A1 | METHODS OF TREATING ORAL MUCOSITIS | BIOSSIL INC. (CA) | 2018-11-22 | — | — | US | disclosed |
| EP-3287464-A1 | ONE POT SYNTHESIS OF TETRAZOLE DERIVATIVES OF SIROLIMUS | Abbott Laboratories (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9855279-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2018-01-02 | — | — | US | disclosed |
| EP-2859916-B1 | Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy | GALERA LABS LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-1997006830-A1 | METHODS OF DIAGNOSTIC IMAGE ANALYSIS USING BIOCONJUGATES OF METAL COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS | MONSANTO COMPANY (US) | 1997-02-27 | — | — | WO | disclosed |
| EP-0756495-A1 | DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES | MONSANTO COMPANY (US) | 1997-02-05 | — | — | EP | disclosed |
| WO-1996040658-A1 | PROCESS FOR PREPARING SUBSTITUTED POLYAZAMACROCYCLES | MONSANTO COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996039396-A1 | MANGANESE OR IRON COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1995028968-A1 | DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES | MONSANTO COMPANY (US) | 1995-11-02 | — | — | WO | disclosed |
| EP-0679155-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE. | MONSANTO CO (US) | 1995-11-02 | — | — | EP | disclosed |
| WO-1994015925-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-07-21 | — | — | WO | disclosed |
| EP-0598753-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| WO-1993002090-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1993-02-04 | — | — | WO | disclosed |
| EP-0524161-A1 | Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide | MONSANTO COMPANY (US) | 1993-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180333421-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | MGLL 1180/4885FAAH 3604/4885TRPV1 2795/4885 |
| US-20200215077-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | MGLL 1180/4885FAAH 3604/4885TRPV1 2795/4885 |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | MGLL 1180/4885FAAH 3604/4885TRPV1 2795/4885 |
| US-10610533-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | MGLL 1180/4885FAAH 3604/4885TRPV1 2795/4885 |
| US-11612608-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | MGLL 1180/4885FAAH 3604/4885TRPV1 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.